OMARINI, Claudia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.699
EU - Europa 5.692
AS - Asia 5.614
SA - Sud America 844
AF - Africa 173
Continente sconosciuto - Info sul continente non disponibili 158
OC - Oceania 33
Totale 24.213
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.370
IT - Italia 1.725
SG - Singapore 1.582
CN - Cina 1.339
GB - Regno Unito 981
IE - Irlanda 833
VN - Vietnam 646
HK - Hong Kong 629
BR - Brasile 600
DE - Germania 517
BD - Bangladesh 371
SE - Svezia 368
FR - Francia 257
RU - Federazione Russa 209
FI - Finlandia 204
IN - India 178
CA - Canada 176
ID - Indonesia 150
KR - Corea 145
UA - Ucraina 114
TR - Turchia 94
AR - Argentina 80
JP - Giappone 72
NL - Olanda 65
BG - Bulgaria 63
IQ - Iraq 63
MX - Messico 59
PL - Polonia 51
LT - Lituania 49
CO - Colombia 46
ES - Italia 46
TW - Taiwan 43
CL - Cile 40
PK - Pakistan 35
ZA - Sudafrica 35
EG - Egitto 34
MY - Malesia 32
EC - Ecuador 31
AU - Australia 30
BE - Belgio 30
CZ - Repubblica Ceca 30
AE - Emirati Arabi Uniti 27
AT - Austria 25
IR - Iran 23
MA - Marocco 23
SA - Arabia Saudita 23
VE - Venezuela 23
NP - Nepal 19
JO - Giordania 18
KE - Kenya 18
RO - Romania 18
PH - Filippine 17
JM - Giamaica 16
TH - Thailandia 16
CR - Costa Rica 14
CH - Svizzera 13
HN - Honduras 12
MD - Moldavia 12
TN - Tunisia 11
UZ - Uzbekistan 11
AZ - Azerbaigian 10
EU - Europa 10
PY - Paraguay 10
SY - Repubblica araba siriana 10
DO - Repubblica Dominicana 9
HU - Ungheria 9
IL - Israele 9
TT - Trinidad e Tobago 9
RS - Serbia 8
BH - Bahrain 7
DZ - Algeria 7
GR - Grecia 7
NG - Nigeria 7
PE - Perù 7
AL - Albania 6
GP - Guadalupe 6
NI - Nicaragua 6
PR - Porto Rico 6
PT - Portogallo 6
SK - Slovacchia (Repubblica Slovacca) 6
AO - Angola 5
CI - Costa d'Avorio 5
ET - Etiopia 5
GH - Ghana 5
HR - Croazia 5
KG - Kirghizistan 5
LB - Libano 5
MT - Malta 5
BO - Bolivia 4
CY - Cipro 4
DK - Danimarca 4
EE - Estonia 4
GA - Gabon 4
LV - Lettonia 4
NO - Norvegia 4
PS - Palestinian Territory 4
SI - Slovenia 4
SV - El Salvador 4
CW - ???statistics.table.value.countryCode.CW??? 3
GT - Guatemala 3
Totale 24.002
Salva come PNG Salva come JPEG
Città #
Ashburn 1.548
Santa Clara 1.059
Singapore 1.037
Dublin 828
San Jose 722
Fairfield 636
Hong Kong 602
Chandler 592
Council Bluffs 515
Dallas 502
Southend 420
Hefei 337
Houston 314
Woodbridge 295
Beijing 285
Seattle 262
Nyköping 259
Wilmington 242
New York 237
Ann Arbor 227
Dearborn 215
London 213
Los Angeles 212
Ho Chi Minh City 204
Cambridge 176
Helsinki 166
Modena 160
Milan 157
The Dalles 151
Jacksonville 150
Chicago 149
Hanoi 144
Seoul 135
Jakarta 111
Munich 107
Shanghai 96
Rome 93
Lauterbourg 89
Bologna 84
San Diego 74
Moscow 73
Buffalo 67
Fremont 62
Sofia 61
Princeton 60
Columbus 59
Frankfurt am Main 58
Redwood City 54
Orem 53
São Paulo 52
Tokyo 52
Phoenix 48
Toronto 46
Eugene 44
Dong Ket 41
Salt Lake City 40
Warsaw 39
Baghdad 38
Izmir 37
Brooklyn 34
Guangzhou 34
Bremen 33
Enfield 32
Parma 32
Boardman 30
Reggio Emilia 30
Denver 29
Mumbai 29
Tampa 29
Atlanta 27
Elk Grove Village 26
Portsmouth 26
San Giuliano Milanese 26
Da Nang 25
Falls Church 25
Montreal 25
Paris 25
Redondo Beach 24
Lawrence 22
Nuremberg 22
Santiago 22
Asyut 21
Brussels 21
Newark 21
Miami 20
Chennai 19
Florence 19
Haiphong 19
Naples 19
Amsterdam 18
Dhaka 18
Genoa 18
Johannesburg 18
Kent 18
Mexico City 18
Palermo 18
Philadelphia 17
Poplar 17
Turku 17
Brasília 16
Totale 15.748
Salva come PNG Salva come JPEG
Nome #
Cancer Treatment Induced Bone Loss (CTIBL) in breast cancer women: a multidisciplinary approach at the Modena Cancer Center screening over 600 patients. 655
Endocrine sensitive metastatic breast cancer and bone only disease: are the new treatments always better? 476
ERBB2 mutations in hormone receptor positive primary breast cancers samples and in their matched endocrine-resistant recurrences. 452
Interstitial Lung Disease in Abemaciclib-treated Patients during SARS-CoV-2 Pandemic: A Case Series. 421
Impact of time to surgery after neoadjuvant chemotherapy in operable breast cancer patients 420
Differential molecular pathways expression in HER2 positive early breast cancer according to hormone receptor status. 416
Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going 415
Predictors of human epidermal growth factor receptor 2 fluorescence in-situ hybridisation amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis. 403
Impact of body composition parameters on tumor response to neoadjuvant chemotherapy in operable breast cancer patients. 398
Clinical and molecular analysis of long-term HER2 positive metastatic breast cancer survivors. 397
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: A real-world experience 393
Clinical Prognosticators in Patients Treated with CDK 4/6 Inhibitors for Hormone Receptors Positive Advanced Breast Cancer 387
Axillary Ectopic Carcinoma of the Breast. Report of Two Cases with Different Clinical Presentation and Review of the Literature. 383
Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus 381
Genomic alterations at the basis of treatment resistance in metastatic breast cancer: Clinical applications 380
First-Line Treatment for Endocrine-Sensitive Bone-Only Metastatic Breast Cancer: Systematic Review and Meta-analysis 375
Endocrine-based targeted combination versus endocrine therapy alone as first-line treatment in elderly patients with hormone receptor-positive advanced breast cancer: Meta-analysis of phase II and III randomized clinical trials. 373
Primary and secondary prevention to effectively reduce the risk of bisphosphonate-related osteonecrosis of the jaw in patients with bone metastases . 367
Predictive role of haemoglobin on disease response to neoadjuvant chemotherapy in breast cancer. 351
Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients. 351
Post-surgical pyoderma gangrenosum of the breast: needs for early diagnosis and right therapy. 347
Predictors of HER2 gene amplification in immunohistochemistry score 2+ Early Breast Cancer according to 2018 ASCO/CAP guidelines: a single institution analysis. 342
Thromboembolism (TE) and adjuvant endocrine therapy (AET) in hormone receptor positive (HR+) early breast cancer (EBC): Did the evolution of treatment change the incidence of the adverse event? A metanalysis 342
Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients 341
Clinical-Pathological Characteristics of HER2+ Breast Cancers patients among BRCA1/2+ carriers tested in Modena Cancer Center. 332
Modulation of Mutational Landscape in HER2-Positive Breast Cancer after Neoadjuvant Chemotherapy 331
Metronomic Capecitabine Effectively Blocks Leptomeningeal Carcinomatosis From Breast Cancer: A Case Report and Literature Review. 330
Safety and efficacy of T-DM1 in HER2 positive metastatic breast cancer patients: a real word experience. 329
Impact of time to surgery after neoadjuvant chemotherapy in patients with operable breast cancer. 328
Differential gene expression patterns in HER2 positive metastatic breast cancer patients according to hormone receptor status 327
Molecular profile in primary and metastatic breast cancer treated with Exemestane and Everolimus. 327
Immune characterization of breast cancer metastases: prognostic implications. 326
Osteonecrosis of the Jaw in a Breast Cancer Patient Treated with Everolimus and a Single Dose of Zoledronic Acid. 322
Predictive factors for relapse in triple-negative breast cancer patients without pathological complete response after neoadjuvant chemotherapy 315
PROFILO MUTAZIONALE DI TUMORI MAMMARI HER2 POSITIVI TRATTATI CON CHEMIOTERAPIA NEOADIUVANTE​ 315
Prognostic significance of germline BRCA mutations in patients with HER2-positive breast cancer. Epidemiological analysis in primary BRCA screens 314
Predictive Role Of Body Composition Parameters In Operable Breast Cancer Patients Treated With Neoadjuvant Chemotherapy. 311
Real-World Data and Clinical Implications of Next-Generation Sequencing (NGS)-Based Analysis in Metastatic Breast Cancer Patients 303
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 296
Two-month stop in mammographic screening significantly impacts on breast cancer stage at diagnosis and upfront treatment in the COVID era 293
Impact of anaemia on tumor response to neoadjuvant chemotherapy in breast cancer patients . 292
Primary treatment strategy in elderly patients with hormone receptor positive early breast cancer: is breast cancer surgery. 287
Adjuvant exemestane or tamoxifen plus ovarian suppression in premenopausal women: single institution analysis 284
Prognostic impact of estrogen receptor (ER) level changes during progression for patients with both ER-positive (ER+) primary breast cancer and paired recurrence 283
Differential gene expression patterns in HER2 positive metastatic breast cancer patients according to hormone receptor status. 281
PROGNOSIS AND RESPONSE TO NEOADJUVANT CHEMOTHERAPY ACCORDING TO HER2 EXPRESSION IN EARLY BREAST CANCER: a retrospective single institution analysis 279
Targeting PI3K/AKT/mTOR Pathway in Breast Cancer: From Biology to Clinical Challenges 274
First-line treatment for endocrine sensitive bone-only metastatic breast cancer: Is more always better? 273
Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: To prescribe for the patient or the physician? A meta-analysis of phase II and III randomized clinical trials 270
First-line treatment for endocrine sensitive bone-only metastatic breast cancer: Is more always better? 268
The role of exosomes in breast cancer diagnosis 267
T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis 259
Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients. 258
Breast cancer follow-up: a national survey of current clinical practice by the centers of Italian Oncological Group of Clinical Research (GOIRC). 254
TDM-1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: A meta-analysis 253
Pre and post anti Her-2 therapy era: a mono-institutional analysis of the outcome in patients with residual disease after neoadjuvant therapy for Her-2 positive locally advanced breast cancer. 245
Role of Intrinsic Subtype Analysis with PAM50 in Hormone Receptors Positive HER2 Negative Metastatic Breast Cancer: A Systematic Review. 241
Quality of life of therapies for hormone receptor positive advanced/metastatic breast cancer: Regulatory aspects and clinical impact in Europe 239
Next Generation Sequencing (NGS): a possible game changer in metastatic breast cancer 238
Circulating and Intracellular miRNAs as Prognostic and Predictive Factors in HER2-Positive Early Breast Cancer Treated with Neoadjuvant Chemotherapy: A Review of the Literature 237
EV derived miR-21 as a promising biomarker for early diagnosis and tumor activity in discrete BC subtypes: The Exobreast project 236
Lapatinib and renal impairment: a case report 236
Cancer treatment during the coronavirus disease 2019 pandemic: Do not postpone, do it! 233
A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study 229
Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affectclinical outcome of metastatic breast cancer patients 225
Quantitative expression of estrogen receptor on relapse biopsy for ER-positive breast cancer: prognostic impact 224
Thromboembolism and Adjuvant Endocrine Therapy (AET) in Hormone Receptor-Positive Early Breast Cancer (EBC): Did Treatment Evolution Change Incidence of the Adverse Event? A Meta-Analysis 222
Prognostic role of HER2 loss after neoadjuvant therapy in patients with HER2-positive operable breast cancer 219
Efficacy and safety of neoadjuvant chemotherapy plus trastuzumab and pertuzumab in non-metastatic HER2-positive breast cancer in real life: NEOPEARL study. 217
Adjuvant Endocrine Therapy in Premenopausal Women With Hormone Receptor-Positive Early-Stage Breast Cancer: Risk Stratification in a Real-World Setting 216
Ocular Toxicity in Breast Cancer Management: Manual for The Oncologist 198
Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclib 194
Extracellular vesicles-derived miR-21 as a biomarker for early diagnosis and tumor activity in breast cancer subtypes 187
Safety and efficacy analysis of neoadjuvant pertuzumab, trastuzumab and standard chemotherapy for HER2–positive early breast cancer: real–world data from NeoPowER study 180
Quality of life of therapies for hormone receptor positive advanced/metastatic breast cancer (HR+/HER2- mBC): regulatory aspects and clinical impact in Europe 178
TDM-1 efficacy in trastuzumabpertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis 176
The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer 162
Atezolizumab-Related Sarcoidosis-Like Reaction in Early Breast Cancer Patient: Know It To Diagnose It: A Case Report with Review of the Literature 161
Prognostic significance of germline BRCA mutations in patients with HER2-POSITIVE breast cancer. 160
Pneumonitis and pulmonary fibrosis associated with breast cancer treatments 158
Reply to comments on: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients 112
Spotlight on triptorelin in the treatment of premenopausal women with early-stage breast cancer 107
Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: to prescribe for the patient or the physician? A meta-analysis of phase II and III randomized clinical trials. BMC Cancer 36
Totale 24.213
Salva come PNG Salva come JPEG
Categoria #
all - tutte 88.105
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 88.105
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.027 0 0 0 58 51 110 63 71 131 126 251 166
2022/20232.647 191 266 146 186 174 202 47 156 960 50 168 101
2023/20241.429 75 65 102 138 175 130 160 211 54 64 102 153
2024/20254.164 141 53 127 268 814 592 319 257 410 286 335 562
2025/20268.506 567 251 924 798 1.108 510 1.047 441 806 789 712 553
2026/20271.938 256 418 617 647 0 0 0 0 0 0 0 0
Totale 24.213